Compass Therapeutics (CMPX) Total Debt (2019 - 2021)

Compass Therapeutics (CMPX) has 3 years of Total Debt data on file, last reported at $3.7 million in Q3 2021.

• For the quarter ending Q3 2021, Total Debt fell 66.54% year-over-year to $3.7 million; the trailing twelve-month figure through Sep 2021 stood at $3.7 million (down 66.54% YoY), and the FY2020 full-year result was $9.3 million, down 37.23% from the prior year.
• Total Debt eased to $3.7 million in Q3 2021, from $7.5 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $14.9 million in Q4 2019 to a low of $3.7 million in Q3 2021.
• A 3-year average of $9.9 million and a median of $10.3 million in 2020 frame the typical range for Total Debt.
• Across the five-year window, Total Debt plunged 37.23% in 2020 and slumped 66.54% in 2021, its largest moves.
• Tracing CMPX's Total Debt over 3 years: stood at $14.9 million in 2019, then sank by 37.23% to $9.3 million in 2020, then sank by 59.89% to $3.7 million in 2021.
• Business Quant data shows CMPX's Total Debt at $3.7 million in Q3 2021, $7.5 million in Q1 2021, and $9.3 million in Q4 2020.